Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Richard E. Pratley MD Associate Editor

Kathleen M. Dungan MD, MPH Advisory Board

Silvio E. Inzucchi MD Editor-in-Chief

See All Experts

featured

Published in Diabetes

Expert Opinion / Commentary · December 02, 2019

2019 Top Stories in Diabetes: Double Agents: SGLT2 inhibitors Show Efficacy in Heart Failure and Chronic Kidney Disease

Written by

Kathleen M. Dungan MD, MPH

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Sign in

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Kathleen Dungan MD, MPH

story of the week

Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes — 2025

Diabetes Care · December 30, 2024

updated
featured

Efficiency of CGM in Predicting Gestational Diabetes and Perinatal Complications

Diabetes Technol. Ther. · December 30, 2024

updated
featured

Effect of Sarcopenic Obesity on the Progression of Glycaemic Status in Middle-Aged and Older Adults Without Diabetes

Diabetes Obes Metab · December 29, 2024

updated
story of the week

Use of SGLT2 Inhibitors Reduces Epicardial Adipose Tissue More Effectively Compared With GLP-1 Agonists or Exercise in Patients With Type 2 Diabetes and/or Obesity

Diabetes Obes Metab · December 26, 2024
featured

Prevalence of Metabolic Syndrome Among Children and Adolescents With Obesity

Obesity · December 26, 2024
featured

Improving Care and Promoting Health in Populations: Standards of Care in Diabetes — 2025

Diabetes Care · December 25, 2024
featured

Perinatal Outcomes in Patients With Early vs Late Gestational Diabetes Mellitus Treated Between 24 and 28 Weeks of Gestation

Diabetes Care · December 23, 2024

updated
featured

Association Between Bone Mineral Density and the Risk of Kidney Disease Progression in Patients With Type 1 Diabetes

J Diabetes Complicat · December 23, 2024
featured

Role of Intermittent Fasting in Weight Management and Improving Metabolic Health

Diabetes Obes Metab · December 19, 2024
featured

Consensus Considerations and Good Practice Points for the Use of CGM Systems in Hospital Settings

Diabetes Care · December 19, 2024
featured

Weight Changes After Treatment With Semaglutide in Individuals With MASLD/MASH With or Without Type 2 Diabetes

Diabetes Obes Metab · December 18, 2024

2019 Top Stories in Diabetes: Double Agents: SGLT2 inhibitors Show Efficacy in Heart Failure and Chronic Kidney Disease

Additional Info

Further Reading

Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes — 2025

Efficiency of CGM in Predicting Gestational Diabetes and Perinatal Complications

Effect of Sarcopenic Obesity on the Progression of Glycaemic Status in Middle-Aged and Older Adults Without Diabetes

Use of SGLT2 Inhibitors Reduces Epicardial Adipose Tissue More Effectively Compared With GLP-1 Agonists or Exercise in Patients With Type 2 Diabetes and/or Obesity

Prevalence of Metabolic Syndrome Among Children and Adolescents With Obesity

Improving Care and Promoting Health in Populations: Standards of Care in Diabetes — 2025

Perinatal Outcomes in Patients With Early vs Late Gestational Diabetes Mellitus Treated Between 24 and 28 Weeks of Gestation

Association Between Bone Mineral Density and the Risk of Kidney Disease Progression in Patients With Type 1 Diabetes

Role of Intermittent Fasting in Weight Management and Improving Metabolic Health

Consensus Considerations and Good Practice Points for the Use of CGM Systems in Hospital Settings

Weight Changes After Treatment With Semaglutide in Individuals With MASLD/MASH With or Without Type 2 Diabetes

Recently Updated